NFX Stock Overview
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuformix plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.002 |
| 52 Week High | UK£0.0044 |
| 52 Week Low | UK£0.0018 |
| Beta | 0.29 |
| 1 Month Change | 5.26% |
| 3 Month Change | -48.72% |
| 1 Year Change | -18.37% |
| 3 Year Change | -91.27% |
| 5 Year Change | -94.07% |
| Change since IPO | -94.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| NFX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.4% | 8.3% | 2.2% |
| 1Y | -18.4% | 4.9% | 0.9% |
Price Volatility
| NFX volatility | |
|---|---|
| NFX Average Weekly Movement | 13.8% |
| Pharmaceuticals Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Volatility Over Time: NFX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 3 | n/a | www.nuformix.com |
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Nuformix plc Fundamentals Summary
| NFX fundamental statistics | |
|---|---|
| Market cap | UK£1.64m |
| Earnings (TTM) | -UK£572.98k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs NFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NFX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£572.98k |
| Earnings | -UK£572.98k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0007 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NFX perform over the long term?
See historical performance and comparison